Persistent left superior vena cava is associated with complex atrial tachyarrhythmias in repaired tetralogy of Fallot: evidence for a right-sided arrhythmogenic substrate

持续性左侧上腔静脉与法洛四联症术后患者的复杂性房性心动过速相关:提示存在右侧致心律失常基质。

阅读:1

Abstract

BACKGROUND: Atrial fibrillation (AF) is an important late complication in patients with repaired tetralogy of Fallot (TOF); however, its clinical determinants and arrhythmogenic substrates remain uncertain. Identifying high-risk anatomical profiles is essential for optimal rhythm management and tailored ablation strategies. METHODS: We retrospectively analyzed 137 consecutive patients with repaired TOF followed at the University of Tsukuba Hospital (2013-2024). Clinical characteristics, echocardiographic parameters, and procedural findings were compared between patients with and without AF. Logistic regression identified independent predictors. Catheter ablation approaches and outcomes were evaluated in patients who underwent AF ablation. RESULTS: AF occurred in 14 patients (10.2%), frequently coexisting with atrial tachycardia (78.6%). Compared with patients without AF, those with AF were older, had undergone more repeat cardiac surgeries, and more commonly exhibited a persistent left superior vena cava (PLSVC), greater biatrial enlargement, and mildly reduced right ventricular function. On multivariable analysis, PLSVC remained statistically associated with AF (odds ratio 15.5, p = 0.002); however, this association was primarily driven by patients with combined AF and AT, as no PLSVC was observed in the small isolated AF subgroup. Among six patients who underwent catheter ablation, those without PLSVC were successfully treated with pulmonary vein isolation (PVI) alone, whereas two patients with PLSVC underwent right-sided ablation targeting the right atrium and coronary sinus, with no AF recurrence observed during follow-up. CONCLUSIONS: PLSVC was associated with more complex atrial tachyarrhythmias, particularly in patients with concomitant AF and AT. Recognizing this substrate may inform individualized ablation strategies beyond conventional PVI.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。